Summit Therapeutics Inc. Restricted Cash, Current
Summit Therapeutics Inc. (SMMT) had Restricted Cash, Current of $317.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-07-23
- 2026-06-30: Restricted Cash, Current $317.00K.
- 2026-03-31: Restricted Cash, Current $316.00K.
- 2025-12-31: Restricted Cash, Current $316.00K.
- 2025-09-30: Restricted Cash, Current $321.00K.
| Period end | Restricted Cash, Current |
|---|---|
| 2026-06-30 | $317.00K 10-Q · filed 2026-07-23 |
| 2026-03-31 | $316.00K 10-Q · filed 2026-04-30 |
| 2025-12-31 | $316.00K 10-Q · filed 2026-07-23 |
| 2025-09-30 | $321.00K 10-Q · filed 2025-10-20 |
| 2025-06-30 | $319.00K 10-Q · filed 2026-07-23 |
| 2025-03-31 | $318.00K 10-Q · filed 2026-04-30 |
| 2024-12-31 | $325.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $323.00K 10-Q · filed 2025-10-20 |
| 2024-06-30 | $320.00K 10-Q · filed 2025-08-11 |
| 2024-03-31 | $317.00K 10-Q · filed 2025-05-01 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-23 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 |
| 2022-12-31 | $300.00M 10-K · filed 2025-02-24 |
| 2022-12-15 | $300.00M 10-K · filed 2025-02-24 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |